ConductScience.org, home

Paper25965342

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.

Mohni KN and 7 others. PLoS One, 2015. Cited by 89 papers, by iCite.

Cite this record

ConductScience Library. A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments. Papers, record 25965342. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25965342

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments.
PubMed
Journal
PLoS One
PubMed
Year
2015
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
89
iCite
Relative citation ratio, by iCite
2.19
iCite
Revised in PubMed
2020-12-17
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mohni KNKareem N
2Thompson PSPetria S
3Luzwick JWJessica W
4Glick GGGloria G
5Pendleton CSChristopher S
6Lehmann BDBrian D
7Pietenpol JAJennifer A
8Cortez DDavid

Source PubMed

Download CSV of authors

Topics18

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
CisplatinMajor topic
DNA RepairMajor topic
PyrazinesMajor topic
SulfonesMajor topic
Ataxia Telangiectasia Mutated Proteins
Cell Line, Tumor
Cell Survival
DNA-Directed DNA Polymerase
Drug Resistance, Neoplasm
Drug Synergism
Gene Library
HCT116 Cells
Humans
Intracellular Signaling Peptides and Proteins
RNA, Small Interfering
Tumor Suppressor p53-Binding Protein 1

Source PubMed

Download CSV of topics

Grants8

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
T32 CA009582NCI NIH HHSUnited StatesT32CA009582PubMed and NIHNIH RePORTER
CA95131NCI NIH HHSUnited StatesPubMedPubMed
R01 CA102792NCI NIH HHSUnited StatesR01CA102792PubMed and NIHNIH RePORTER
R01 CA102729NCI NIH HHSUnited StatesR01CA102729PubMed and NIHNIH RePORTER
T32CA093240NCI NIH HHSUnited StatesT32CA093240PubMed and NIHNIH RePORTER
T32 GM007347NIGMS NIH HHSUnited StatesT32GM007347PubMedNIH RePORTER
T32 CA093240NCI NIH HHSUnited StatesT32CA093240PubMed and NIHNIH RePORTER
CA102792NCI NIH HHSUnited StatesR01CA102792PubMed and NIHNIH RePORTER

Download CSV of grants

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
120125090Management of breast cancer with targeted agents: importance of heterogeneity. [corrected].Nat Rev Clin Oncol2010https://conductscience.org/library/papers/20125090PubMed
223548269ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.Cancer Res2013https://conductscience.org/library/papers/23548269PubMed
315829956DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis.Nature2005https://conductscience.org/library/papers/15829956PubMed
42045385853BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.Nat Struct Mol Biol2010https://conductscience.org/library/papers/20453858PubMed
523118055Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.Cancer Res2012https://conductscience.org/library/papers/23118055PubMed
612370818Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors.Oncogene2002https://conductscience.org/library/papers/12370818PubMed
79307278Correction of hypermutability, N-methyl-N'-nitro-N-nitrosoguanidine resistance, and defective DNA mismatch repair by introducing chromosome 2 into human tumor cells with mutations in MSH2 and MSH6.Cancer Res1997https://conductscience.org/library/papers/9307278PubMed
821069451Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features.Breast Cancer Res Treat2011https://conductscience.org/library/papers/21069451PubMed
921565612Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11.Cell2011https://conductscience.org/library/papers/21565612PubMed
102036232553BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.Cell2010https://conductscience.org/library/papers/20362325PubMed
1115829965Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions.Nature2005https://conductscience.org/library/papers/15829965PubMed
122088205A three-dimensional model to analyze drug-drug interactions.Antiviral Res1990https://conductscience.org/library/papers/2088205PubMed
1315701627Poly(ADP-ribose) polymerase activity prevents signaling pathways for cell cycle arrest after DNA methylating agent exposure.J Biol Chem2005https://conductscience.org/library/papers/15701627PubMed
1423394205
Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity.
J Med Chem2013https://conductscience.org/library/papers/23394205PubMed
1522047021Translesion DNA synthesis in the context of cancer research.Cancer Cell Int2011https://conductscience.org/library/papers/22047021PubMed
1620573551Alkylation DNA damage in combination with PARP inhibition results in formation of S-phase-dependent double-strand breaks.DNA Repair (Amst)2010https://conductscience.org/library/papers/20573551PubMed
1715829966Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.Nature2005https://conductscience.org/library/papers/15829966PubMed
1824662920ATR pathway inhibition is synthetically lethal in cancer cells with ERCC1 deficiency.Cancer Res2014https://conductscience.org/library/papers/24662920PubMed
1922246237Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.Mol Cancer Res2012https://conductscience.org/library/papers/22246237PubMed
2018594563ATR: an essential regulator of genome integrity.Nat Rev Mol Cell Biol2008https://conductscience.org/library/papers/18594563PubMed

See all 51 referencesDownload CSV of references

Cited by60

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 89 citations.

PMIDTitleJournalYearIn PapersSource
42882893Chk1/2 Inhibition by AZD7762 Enhances Andrographolide-Induced DNA Damage, Impairs DNA Repair, and Promotes Apoptosis in Head and Neck Squamous Cell Carcinoma CAL-33 Cells.Cancers (Basel)2026https://conductscience.org/library/papers/42882893PubMed
40067909NEMO is essential for directing the kinases IKKα and ATM to the sites of DNA damage.Sci Signal2025https://conductscience.org/library/papers/40067909PubMed
39841295Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406).Cancer Chemother Pharmacol2025https://conductscience.org/library/papers/39841295PubMed
39707666Synergistic Potential of Argentatins A and B to Improve 5-Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models.J Cell Mol Med2024https://conductscience.org/library/papers/39707666PubMed
39156700Combined strategies with PARP inhibitors for the treatment of BRCA wide type cancer.Front Oncol2024https://conductscience.org/library/papers/39156700PubMed
39135999Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer.Front Oncol2024https://conductscience.org/library/papers/39135999PubMed
38201511Exploiting the DNA Damage Response for Prostate Cancer Therapy.Cancers (Basel)2023https://conductscience.org/library/papers/38201511PubMed
38041093The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.J Transl Med2023https://conductscience.org/library/papers/38041093PubMed
37511442Novel Cellular Functions of ATR for Therapeutic Targeting: Embryogenesis to Tumorigenesis.Int J Mol Sci2023https://conductscience.org/library/papers/37511442PubMed
37444534State-of-the-Art and Upcoming Innovations in Pancreatic Cancer Care: A Step Forward to Precision Medicine.Cancers (Basel)2023https://conductscience.org/library/papers/37444534PubMed
36810257The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy.JCI Insight2023https://conductscience.org/library/papers/36810257PubMed
36644397ATR inhibition overcomes platinum tolerance associated with ERCC1- and p53-deficiency by inducing replication catastrophe.NAR Cancer2023https://conductscience.org/library/papers/36644397PubMed
36413415ATR represents a therapeutic vulnerability in clear cell renal cell carcinoma.JCI Insight2022https://conductscience.org/library/papers/36413415PubMed
36130512Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression.Cell Rep2022https://conductscience.org/library/papers/36130512PubMed
35205643Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition.Cancers (Basel)2022https://conductscience.org/library/papers/35205643PubMed
34964992Pharmacologic inhibition of ataxia telangiectasia and Rad3-related (ATR) in the treatment of head and neck squamous cell carcinoma.Mol Carcinog2022https://conductscience.org/library/papers/34964992PubMed
34224364VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases.Mol Cancer Ther2021https://conductscience.org/library/papers/34224364PubMed
34027408Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors.NAR Cancer2021https://conductscience.org/library/papers/34027408PubMed
34021944Homologous Recombination Deficiency: Cancer Predispositions and Treatment Implications.Oncologist2021https://conductscience.org/library/papers/34021944PubMed
33905873Critical DNA damaging pathways in tumorigenesis.Semin Cancer Biol2022https://conductscience.org/library/papers/33905873PubMed

See all 60 cited byDownload CSV of cited by

Genes28

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ATM472PubTator's text mininghttps://conductscience.org/library/genes/472NCBI Gene
ATR545PubTator's text mininghttps://conductscience.org/library/genes/545NCBI Gene
ATRIP84126PubTator's text mininghttps://conductscience.org/library/genes/84126NCBI Gene
BRCA1672PubTator's text mininghttps://conductscience.org/library/genes/672NCBI Gene
BRCA2675PubTator's text mininghttps://conductscience.org/library/genes/675NCBI Gene
CHEK11111PubTator's text mininghttps://conductscience.org/library/genes/1111NCBI Gene
DDB21643PubTator's text mininghttps://conductscience.org/library/genes/1643NCBI Gene
ERCC12067PubTator's text mininghttps://conductscience.org/library/genes/2067NCBI Gene
ERCC42072PubTator's text mininghttps://conductscience.org/library/genes/2072NCBI Gene
INTS365123PubTator's text mininghttps://conductscience.org/library/genes/65123NCBI Gene
MAD2L210459PubTator's text mininghttps://conductscience.org/library/genes/10459NCBI Gene
MSH24436PubTator's text mininghttps://conductscience.org/library/genes/4436NCBI Gene
MSH34437PubTator's text mininghttps://conductscience.org/library/genes/4437NCBI Gene
MSH62956PubTator's text mininghttps://conductscience.org/library/genes/2956NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene
PARP210038PubTator's text mininghttps://conductscience.org/library/genes/10038NCBI Gene
PARP4143PubTator's text mininghttps://conductscience.org/library/genes/143NCBI Gene
POLD25425PubTator's text mininghttps://conductscience.org/library/genes/5425NCBI Gene
RAD5010111PubTator's text mininghttps://conductscience.org/library/genes/10111NCBI Gene
RAD54L8438PubTator's text mininghttps://conductscience.org/library/genes/8438NCBI Gene

See all 28 genesDownload CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25965342

GET https://conductscience.org/api/papers/v1/25965342/references?page=2